Abstract
A pilot study of the use of Anafranil in the treatment of phobic disorders is described. Twenty-two patients were included in the investigation, 16 receiving intravenous and oral Anafranil combined and six oral Anafranil alone. After one month, four were free of phobic symptoms and 13 only mildly disabled. At six month follow-up 10 were free of symptoms and seven only mildly disabled.

This publication has 4 references indexed in Scilit: